2. Methods:
We enrolled 97 consecutive patients with at least one cardiovascular risk factor [Hypertension (blood pressure ≥130/80 mmHg or on anti-hypertensive treatment), Type 2 Diabetes mellitus (Hba1c ≥6.5 or on anti-diabetic treatment), dyslipidaemia (total cholesterol ≥200 mg/dl or LDL-C ≥130 mg/dl or on lipid lowering drugs) or Tobacco use (current smoker or tobacco chewing)] who were undergoing CTA for chest pain evaluation over a period of 12 months (January 2019 to February 2020) at the Cardio Thoracic Centre, All India Institute of Medical Sciences (AIIMS) New Delhi. Transthoracic echocardiography was performed in all patients for EAT-T measurements in parasternal long axis (PLAX) and parasternal short axis (PSAX) view, while CTA was reviewed for CAD, CAC score and EAT-V measurements. All patients included were assessed with detailed history, clinical examination and biochemical tests (blood sugar, blood pressure, lipid profile). The exclusion criteria were: (a) patients with known CAD, (b) patients with un-interpretable CT quality, (c) patients with poor echo window, and (d) those not consenting to participate.